XNAS
PRLD
Market cap61mUSD
Jul 11, Last price
0.81USD
1D
-8.16%
1Q
15.04%
IPO
-97.07%
Name
Prelude Therapeutics Inc
Chart & Performance
P/E
—
P/S
8.86
EPS
—
Div Yield, %
—
Shrs. gr., 5y
18.53%
Rev. gr., 5y
%
Revenues
7m
Net income
-127m
L+4.38%
CFO
-103m
L-3.90%
Earnings
Aug 11, 2025
Profile
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | |||||||
Revenues | 7,000 | ||||||
Cost of revenue | 146,714 | 133,446 | 126,582 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (139,714) | (133,446) | (126,582) | ||||
NOPBT Margin | |||||||
Operating Taxes | (8,102) | ||||||
Tax Rate | |||||||
NOPAT | (139,714) | (133,446) | (118,480) | ||||
Net income | (127,173) 4.38% | (121,832) 13.51% | (107,336) -3.11% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 379 | 135,731 | 389 | ||||
BB yield | -0.39% | -52.67% | -0.14% | ||||
| Debt | |||||||
Debt current | 2,700 | 2,962 | 1,832 | ||||
Long-term debt | 33,350 | 32,295 | 1,832 | ||||
Deferred revenue | |||||||
Other long-term liabilities | 3,090 | 3,339 | 3,361 | ||||
Net debt | (97,564) | (197,678) | (202,108) | ||||
| Cash flow | |||||||
Cash from operating activities | (102,888) | (107,063) | (83,729) | ||||
CAPEX | (764) | (3,513) | (3,019) | ||||
Cash from investing activities | 90,191 | (34,646) | 81,691 | ||||
Cash from financing activities | (120) | 136,395 | 815 | ||||
FCF | (137,443) | (164,483) | (119,544) | ||||
| Balance | |||||||
Cash | 133,614 | 232,935 | 201,728 | ||||
Long term investments | 4,044 | ||||||
Excess cash | 133,264 | 232,935 | 205,772 | ||||
Stockholders' equity | (583,524) | (456,162) | (336,245) | ||||
Invested Capital | 736,098 | 714,960 | 536,875 | ||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 75,806 | 60,357 | 47,372 | ||||
Price | 1.28 -70.14% | 4.27 -29.30% | 6.04 -51.49% | ||||
Market cap | 96,652 -62.50% | 257,725 -9.93% | 286,124 -51.72% | ||||
EV | (912) | 60,047 | 84,016 | ||||
EBITDA | (137,942) | (132,277) | (125,258) | ||||
EV/EBITDA | 0.01 | ||||||
Interest | 1,324 | ||||||
Interest/NOPBT | |||||||